Brief Research ReportPublished 27 July 2026Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT studyBolette Christophersen · John Fullarton · Rachel WestFrontiers in Gastroenterologydoi 10.3389/fgstr.2026.1874051
